Gifford Bioscience is a preclincal contract research organisation (CRO). We specialize in receptor pharmacology and occupancy for neurology, oncology and metabolic diseases. Our receptor-ligand binding assays provide critical insight for early stage drug discovery and preclinical research.
Our PhD level scientists are experts in gold-standard radiometric methods and in advanced label-free, kinetic affinity techniques. Our customized assays use human tissue, animal tissues, cultured cells, membranes and recombinant proteins. We work with leading pharma, biotech and university researchers, worldwide.
Determination of receptor affinities and ligand binding parameters for test compounds in a tissue homogenate or cell preparation.
Imaging the distribution of a labeled test drug in tissue sections. Quantification of ligand binding in regions of interest.
Click here to
get in touch
Measurement of the degree to which a test compound engages its target receptor in tissues or in an animal.
Measurement of a compounds transport into cells or efflux from cells. Determination of a compound’s potency and efficacy.
Kinetic, label-fee measurement of a drug’s affinity for its receptor using Surface Plasmon Resonance (SPR).
Measurement of second messenger levels resulting from ligand binding. Determination of potency and efficacy of compounds and identification of agonists and antagonists.
Additional Services
as part of a core receptor pharmacology study
Ancillary Services
as part of a core receptor pharmacology study
Custom Radiolabeling
Human and Animal Tissue
ELISAs
Cell Culture & Transfections
Latest News
Autoradiography in Cancer Research
The role of autoradiography in cancer research. Auoradiography uses radiolabeled compounds to map receptor...
Biased Agonism, Partial Agonism and the Importance of Comprehensive Functional Screening in Drug Development
Read Dr Mark Bird's blog about the importance of measuring the G-protein in biased agonism and partial...
Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA, published in Frontiers in Neuroscience (vol 18, Feb 2024).
Gifford Bioscience contributes its receptor pharmacology expertise to the study of the effect of methylone...
Who We Are
87% recurring customers
53% US customers, 33% in Europe
100% PhD level scientists
Contact Us
This site is protected by reCAPTCHA. The information you supply will be processed in accordance with the General Data Protection Regulation (EU & UK). For further details, please refer to our Privacy Policy.
Copyright © 2025 Gifford Bioscience Limited
Privacy Policy